TG Therapeutics (NASDAQ:TGTX) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of TG Therapeutics (NASDAQ:TGTX) from a buy rating to a hold rating in a report issued on Saturday morning.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright assumed coverage on shares of TG Therapeutics in a research report on Monday, October 6th. They set a “buy” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 1st. Finally, B. Riley raised TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $50.25.

TG Therapeutics Stock Down 2.0%

Shares of NASDAQ:TGTX opened at $30.76 on Friday. The company has a market capitalization of $4.88 billion, a price-to-earnings ratio of 11.06 and a beta of 2.01. TG Therapeutics has a 12-month low of $25.28 and a 12-month high of $46.48. The business has a 50-day moving average price of $33.47 and a 200 day moving average price of $33.80. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The company had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. During the same quarter last year, the firm posted $0.02 earnings per share. TG Therapeutics’s revenue was up 92.7% compared to the same quarter last year. Sell-side analysts expect that TG Therapeutics will post 0.08 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $32.57, for a total transaction of $162,850.00. Following the sale, the director owned 223,816 shares in the company, valued at $7,289,687.12. This represents a 2.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sagar Lonial sold 20,852 shares of the stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. This represents a 18.15% decrease in their position. The disclosure for this sale is available in the SEC filing. 10.64% of the stock is currently owned by company insiders.

Institutional Trading of TG Therapeutics

Large investors have recently made changes to their positions in the company. Ameritas Advisory Services LLC purchased a new position in TG Therapeutics in the second quarter worth approximately $25,000. Johnson Financial Group Inc. purchased a new stake in shares of TG Therapeutics in the 2nd quarter valued at approximately $25,000. Danske Bank A S acquired a new stake in shares of TG Therapeutics in the 3rd quarter valued at $25,000. Optiver Holding B.V. lifted its position in shares of TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 732 shares during the last quarter. Finally, Bessemer Group Inc. grew its stake in shares of TG Therapeutics by 117.1% during the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.